RBC Capital Steps Aside on Global Blood Therapeutics (GBT), 'Oxbryta Beat Confirms Value; With Solid Outcome'
- Wall St set to open lower on China's anti-lockdown protests; Apple slips
- Apple (AAPL) stock dips on China concerns, analyst notes 'significant iPhone shortages'
- Black Friday frenzy generates record $9.1 billion in online sales - report
- Dollar drops, yuan slumps on COVID unrest in China
- Mega cap tech remains under-owned relative to S&P 500 - Morgan Stanley
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
RBC Capital analyst Gregory Renza downgraded Global Blood Therapeutics (NASDAQ: GBT) from Outperform to Sector Perform with a price target of $68.50 (from $60.00).
The analyst comments "Srong Oxbryta revenue beat for 2Q22 and the PFE acquisition underscore the strong fundamentals and value of the SCD platform at GBT, as well as the attractiveness of a safe and efficacious chronic therapy in the SCD space. We had the opportunity to speak to PFE and GBT management teams for additional color. Based on the newly-announced acquisition by PFE, which we believe is highly likely to go through, we are downgrading shares to Sector Perform, adjusting our target to $68.50 to align to the $68.50/share deal price reflecting a $5.4B EV."
Shares of Global Blood Therapeutics closed at $63.84 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades First Solar (FSLR) to Neutral as Easy Money Made
- BofA Securities Downgrades Diamondback Energy (FANG) to Underperform
- JPMorgan Downgrades DraftKings Inc. (DKNG) to Underweight
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Related EntitiesRBC Capital, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!